

# Vered Stearns

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9104972/publications.pdf>

Version: 2024-02-01

192  
papers

16,042  
citations

30070

54  
h-index

16650

123  
g-index

196  
all docs

196  
docs citations

196  
times ranked

16781  
citing authors

#	ARTICLE	IF	CITATIONS
1	CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2005, 97, 30-39.	6.3	867
2	Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1758-1764.	6.3	739
3	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2014, 32, 2255-2269.	1.6	661
4	American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3784-3796.	1.6	655
5	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118.	27.0	621
6	Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5505-5512.	7.0	592
7	Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update. <i>Journal of Clinical Oncology</i> , 2006, 24, 1940-1949.	1.6	579
8	Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells. <i>Cancer Cell</i> , 2012, 21, 430-446.	16.8	564
9	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	27.0	448
10	Paroxetine Controlled Release in the Treatment of Menopausal Hot Flashes. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2827.	7.4	443
11	Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 61-74.	4.7	424
12	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 423-438.	1.6	384
13	Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. <i>Oncotarget</i> , 2014, 5, 587-598.	1.8	367
14	Hot flushes. <i>Lancet</i> , The, 2002, 360, 1851-1861.	13.7	362
15	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1902-1909.	1.6	351
16	Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2643-2650.	7.0	341
17	Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 936-942.	1.6	313
18	Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood. <i>Clinical Cancer Research</i> , 2012, 18, 3462-3469.	7.0	296

#	ARTICLE	IF	CITATIONS
19	Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. <i>Annals of Surgical Oncology</i> , 2002, 9, 235-242.	1.5	251
20	CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2012, 104, 452-460.	6.3	247
21	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. <i>Journal of Clinical Oncology</i> , 2016, 34, 1689-1701.	1.6	243
22	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2838-2847.	1.6	241
23	Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27â€”A Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1398-1404.	1.6	218
24	Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-â€”Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation. <i>Journal of Clinical Oncology</i> , 2009, 27, 5911-5918.	1.6	217
25	Paroxetine Is an Effective Treatment for Hot Flashes: Results From a Prospective Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 6919-6930.	1.6	211
26	Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 365-372.	2.5	200
27	Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors. <i>Journal of Clinical Oncology</i> , 2010, 28, 4674-4682.	1.6	196
28	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Updateâ€”Integration of Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2019, 37, 1956-1964.	1.6	189
29	Prognostic factors in breast cancer: current and new predictors of metastasis. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2001, 6, 375-392.	2.7	184
30	Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. <i>Cancer</i> , 2012, 118, 5937-5946.	4.1	174
31	Newer Antidepressants and Gabapentin for Hot Flashes: An Individual Patient Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2009, 27, 2831-2837.	1.6	162
32	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1816-1837.	1.6	139
33	Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. <i>Clinical Cancer Research</i> , 2015, 21, 3263-3273.	7.0	129
34	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacytidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. <i>Clinical Cancer Research</i> , 2017, 23, 2691-2701.	7.0	106
35	Epigenetics as a Therapeutic Target in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 191-204.	2.7	105
36	Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. <i>Breast Cancer Research</i> , 2011, 13, 205.	5.0	92

#	ARTICLE	IF	CITATIONS
37	Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression. American Journal of Psychiatry, 2008, 165, 1251-1255.	7.2	91
38	Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. Npj Breast Cancer, 2017, 3, 37.	5.2	84
39	A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clinical Cancer Research, 2003, 9, 124-33.	7.0	78
40	A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSFâ€“Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. Cancer Immunology Research, 2014, 2, 949-961.	3.4	77
41	Patientâ€“reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer, 2014, 120, 2403-2411.	4.1	76
42	Epigenetic Regulation as a New Target for Breast Cancer Therapy. Cancer Investigation, 2007, 25, 659-665.	1.3	72
43	Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nature Communications, 2014, 5, 4961.	12.8	72
44	A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma. American Journal of Clinical Pathology, 2016, 145, 365-372.	0.7	72
45	Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nature Reviews Cancer, 2006, 6, 886-893.	28.4	69
46	Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Research and Treatment, 2011, 128, 119-126.	2.5	69
47	Preclinical and Clinical Evaluation of Intraductally Administered Agents in Early Breast Cancer. Science Translational Medicine, 2011, 3, 106ra108.	12.4	66
48	Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Research and Treatment, 2009, 117, 571-575.	2.5	63
49	Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Research and Treatment, 2012, 131, 907-914.	2.5	62
50	TBCRC 008: Early Change in <sup>18</sup> F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2â€“Negative Primary Operable Breast Cancer. Journal of Nuclear Medicine, 2015, 56, 31-37.	5.0	61
51	Racial disparities in the rate of cardiotoxicity of HER2â€“targeted therapies among women with early breast cancer. Cancer, 2018, 124, 1904-1911.	4.1	59
52	A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Research and Treatment, 2012, 131, 915-924.	2.5	57
53	Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precision Oncology, 2017, 2017, 1-19.	3.0	57
54	CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance. Current Oncology Reports, 2010, 12, 7-15.	4.0	56

#	ARTICLE	IF	CITATIONS
55	Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. <i>Oncologist</i> , 2016, 21, 539-546.	3.7	56
56	New therapeutic approaches for hot flashes in women. <i>The Journal of Supportive Oncology</i> , 2003, 1, 11-21; discussion 14-5, 19-21.	2.3	56
57	Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations. <i>Carcinogenesis</i> , 2012, 33, 2242-2249.	2.8	53
58	Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. <i>Oncology</i> , 2008, 22, 1401-8.	0.5	52
59	Pharmacogenetics of Endocrine Therapy for Breast Cancer. <i>Annual Review of Medicine</i> , 2011, 62, 281-293.	12.2	51
60	Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4390-4397.	1.6	51
61	Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 807-816.	2.5	50
62	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 379-386.	7.0	50
63	Estrogen Receptor Genotypes Influence Hot Flash Prevalence and Composite Score Before and After Tamoxifen Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 5849-5854.	1.6	49
64	Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. <i>Cancer</i> , 2014, 120, 381-389.	4.1	49
65	Pharmacogenetics of Tamoxifen: Who Should Undergo CYP2D6 Genetic Testing?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 203-213.	4.9	47
66	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. <i>Cancer Research</i> , 2016, 76, 7012-7023.	0.9	47
67	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1965-1977.	1.6	47
68	Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 474-482.	10.7	45
69	Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors. <i>Psycho-Oncology</i> , 2007, 16, 487-492.	2.3	44
70	Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. <i>JCO Oncology Practice</i> , 2020, 16, 665-674.	2.9	44
71	Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. <i>Oncotarget</i> , 2015, 6, 29143-29160.	1.8	44
72	Neoadjuvant Chemotherapy and Short-term Morbidity in Patients Undergoing Mastectomy With and Without Breast Reconstruction. <i>JAMA Surgery</i> , 2014, 149, 1068.	4.3	43

#	ARTICLE	IF	CITATIONS
73	CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor-Positive Advanced Breast Cancer?. <i>Oncology</i> , 2018, 32, 216-22.	0.5	43
74	Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. <i>Journal of Nuclear Medicine</i> , 2006, 47, 950-6.	5.0	43
75	Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer. <i>Frontiers in Physiology</i> , 2020, 11, 583333.	2.8	42
76	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 763-766.	2.5	41
77	Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 2013-2024.	0.9	40
78	Centrally active nonhormonal hot flash therapies. <i>American Journal of Medicine</i> , 2005, 118, 118-123.	1.5	37
79	A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients?. <i>Journal of the National Cancer Institute</i> , 2008, 100, 610-613.	6.3	36
80	Pharmacogenomics of breast cancer therapy: An update. , 2013, 139, 1-11.		36
81	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	1.6	36
82	Treatment strategies for hot flushes. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1133-1144.	1.8	35
83	A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. <i>Cancer</i> , 2010, 116, 4360-4367.	4.1	35
84	Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 141.	4.1	35
85	Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e34.	3.9	33
86	The role of c-erbB-2 as a predictive factor in breast cancer. <i>Breast Cancer</i> , 2001, 8, 171-183.	2.9	32
87	Clinical update: new treatments for hot flushes. <i>Lancet, The</i> , 2007, 369, 2062-2064.	13.7	32
88	Serotonergic Agents as an Alternative to Hormonal Therapy for the Treatment of Menopausal Vasomotor Symptoms. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2006, 5, 83-87.	1.8	30
89	Increasing Physical Activity Amongst Overweight and Obese Cancer Survivors Using an Alexa-Based Intelligent Agent for Patient Coaching: Protocol for the Physical Activity by Technology Help (PATH) Trial. <i>JMIR Research Protocols</i> , 2018, 7, e27.	1.0	30
90	Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. <i>Academic Radiology</i> , 2018, 25, 1405-1414.	2.5	29

#	ARTICLE	IF	CITATIONS
91	Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1852-1860.	2.0	28
92	Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 263-273.	2.5	27
93	Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4008-4016.	7.0	26
94	Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2022, 10, 656-669.	3.4	26
95	Sentinel Lymphadenectomy After Neoadjuvant Chemotherapy for Breast Cancer May Reliably Represent the Axilla Except for Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2002, 9, 235-242.	1.5	25
96	Management of hormone receptor-positive, HER2-negative early breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 187-200.	2.2	24
97	Can Hypnosis Reduce Hot Flashes in Breast Cancer Survivors? A Literature Review. <i>American Journal of Clinical Hypnosis</i> , 2004, 47, 29-42.	0.6	23
98	Newer antidepressants and gabapentin for hot flashes. <i>Menopause</i> , 2009, 16, 883-887.	2.0	23
99	Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole. <i>Cancer Prevention Research</i> , 2011, 4, 1993-2001.	1.5	23
100	A randomized intervention involving family to improve communication in breast cancer care. <i>Npj Breast Cancer</i> , 2021, 7, 14.	5.2	23
101	The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3024-3034.	7.0	22
102	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	1.6	22
103	Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 201-208.	2.5	21
104	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2704-2710.	7.0	21
105	Current approaches for neoadjuvant chemotherapy in breast cancer. <i>European Journal of Pharmacology</i> , 2013, 717, 58-66.	3.5	19
106	Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 695-706.	2.5	19
107	NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1629-1649.	4.9	18
108	Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1395-1402.	7.0	18

#	ARTICLE	IF	CITATIONS
109	Use of Geriatric Assessment Tools in Selecting Therapies in Women Aged ≥70 Years With Hormone Receptor-Positive Early-Stage Breast Cancer: Preliminary Experience With a Quality Improvement Initiative. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 884-890.	0.8	18
110	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). <i>Clinical Cancer Research</i> , 2021, 27, 5828-5837.	7.0	18
111	Adjuvant radiation use in older women with early-stage breast cancer at Johns Hopkins. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 291-296.	2.5	17
112	Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e1239-e1245.	2.4	17
113	A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 121-129.	2.5	17
114	Sharing in care: engaging care partners in the care and communication of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 127-136.	2.5	17
115	Intraductal fulvestrant for therapy of ER±-positive ductal carcinoma in situ of the breast: a preclinical study. <i>Carcinogenesis</i> , 2019, 40, 903-913.	2.8	17
116	Management of hot flashes in breast cancer survivors and men with prostate cancer. <i>Current Oncology Reports</i> , 2004, 6, 285-290.	4.0	15
117	Statins and Breast Cancer: Future Directions in Chemoprevention. <i>Current Breast Cancer Reports</i> , 2013, 5, 161-169.	1.0	14
118	Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 107-116.	2.5	14
119	High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 25-35.	2.5	14
120	Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2- Advanced Breast Cancer Enrolled in an Expanded Access Program. <i>Clinical Breast Cancer</i> , 2019, 19, 317-325.e4.	2.4	13
121	Randomized trial of two artificial intelligence coaching interventions to increase physical activity in cancer survivors. <i>Npj Digital Medicine</i> , 2021, 4, 168.	10.9	13
122	Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e47-e61.	3.8	12
123	Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 40-46.	2.1	11
124	Considerations for the Use of Scalp Cooling Devices in Black Patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3575-3576.	1.6	11
125	Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. <i>Oncolmmunology</i> , 2020, 9, 1760685.	4.6	11
126	Developing Workshops to Enhance Hope Among Patients With Metastatic Breast Cancer and Oncologists: A Pilot Study. <i>JCO Oncology Practice</i> , 2021, 17, e785-e793.	2.9	11



#	ARTICLE	IF	CITATIONS
127	Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation. <i>Npj Breast Cancer</i> , 2022, 8, 53.	5.2	11
128	A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk with Biomarkers as Surrogate Endpoints for Activity. <i>Clinical Cancer Research</i> , 2004, 10, 8332-8340.	7.0	10
129	Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 411-419.	2.5	10
130	Pathogenic Germline Variants in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1506.	7.1	10
131	Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature. <i>Clinical Breast Cancer</i> , 2022, 22, e65-e73.	2.4	10
132	Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk. <i>Cancer Prevention Research</i> , 2016, 9, 673-682.	1.5	9
133	Dynamic Brain Activity Following Auricular Point Acupressure in Chemotherapy-Induced Neuropathy: A Pilot Longitudinal Functional Magnetic Resonance Imaging Study. <i>Global Advances in Health and Medicine</i> , 2020, 9, 216495612090609.	1.6	9
134	Intraductal therapy for the prevention of breast cancer. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 646-52.	2.3	9
135	The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention. <i>Obesity</i> , 2022, 30, 28-38.	3.0	9
136	Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. <i>Pharmacogenomics</i> , 2007, 8, 1-3.	1.3	8
137	Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 453-461.	2.5	8
138	Further Evidence That OPC rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 662734.	2.3	8
139	Forecasting cancer: from precision to predictive medicine. <i>Med</i> , 2021, 2, 1004-1010.	4.4	8
140	Development of new brain metastases in triple negative breast cancer. <i>Journal of Neuro-Oncology</i> , 2021, 152, 333-338.	2.9	8
141	Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 659-668.	2.5	7
142	Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. <i>Pharmacogenomics</i> , 2019, 20, 571-580.	1.3	7
143	Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 617-624.	2.5	7
144	Association of a low-expression SLCO1B1 polymorphism with estrogen concentrations before and during aromatase inhibitor treatment for breast cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-543.	1.6	7

#	ARTICLE	IF	CITATIONS
145	Effect of simvastatin on the pharmacokinetics of anastrozole. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 709-711.	2.5	6
146	Optimizing Vitamin D Concentrations for Breast Cancer Risk Reduction. <i>Medicine (United States)</i> , 2013, 92, 132-134.	1.0	6
147	Survivorship care visits in a high-risk population of breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 701-708.	2.5	6
148	Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 965-975.	2.5	6
149	A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases. <i>Npj Breast Cancer</i> , 2021, 7, 121.	5.2	6
150	Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. <i>Clinical Breast Cancer</i> , 2021, , .	2.4	6
151	The relationship of single-strand breaks in DNA to breast cancer risk and to tissue concentrations of oestrogens. <i>Biomarkers</i> , 2017, 22, 1-9.	1.9	5
152	The impact of weight loss on physical function and symptoms in overweight or obese breast cancer survivors: results from POWER-remote. <i>Journal of Cancer Survivorship</i> , 2022, 16, 542-551.	2.9	5
153	Chemotherapeutic Strategies for advanced breast cancer. <i>Oncology</i> , 2007, 21, 1325-35; discussion 1338, 1340.	0.5	5
154	Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer. <i>Cancer Research Communications</i> , 2022, 2, 391-401.	1.7	5
155	Adjuvant aromatase inhibitors and emerging quality-of-life considerations. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1-4.	2.4	4
156	Personalized Tamoxifen: A Step Closer but Miles To Go. <i>Clinical Cancer Research</i> , 2010, 16, 4308-4310.	7.0	4
157	Diagnostic accuracy of sentinel node identification is maintained with the addition of local lidocaine and subareolar radioactive colloid injection. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 589-595.	2.5	4
158	TAILORing Adjuvant Systemic Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 191-192.	27.0	4
159	Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 116-123.	1.5	4
160	TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 511-511.	1.6	4
161	Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 437-439.	2.5	3
162	Gene Mutation Profiling of Breast Cancers for Clinical Decision Making. <i>JAMA Oncology</i> , 2015, 1, 569.	7.1	3

#	ARTICLE	IF	CITATIONS
163	Breast Hormone Concentrations in Random Fine-Needle Aspirates of Healthy Women Associate with Cytological Atypia and Gene Methylation. <i>Cancer Prevention Research</i> , 2018, 11, 557-568.	1.5	3
164	PIK3CA Mutations in Hormone Receptor-Positive Breast Cancers. <i>JAMA Oncology</i> , 2018, 4, 1330.	7.1	3
165	Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 297-303.	2.5	3
166	Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008).. <i>Journal of Clinical Oncology</i> , 2012, 30, 10509-10509.	1.6	3
167	The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance) Tj ETQq1 1 0.784314 rgBT /Overwe	1.0	2
168	The role of pharmacogenetics in selection of breast cancer treatment. <i>Current Breast Cancer Reports</i> , 2009, 1, 190-197.	1.0	2
169	Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report. <i>Clinical Breast Cancer</i> , 2018, 18, e277-e280.	2.4	2
170	Adjuvant Endocrine Therapy. , 2018, , 736-751.e4.		2
171	Innovating and expanding weight loss strategies for breast cancer survivors. <i>Oncotarget</i> , 2021, 12, 521-524.	1.8	2
172	Late effects in a high-risk population of breast cancer survivors. <i>Supportive Care in Cancer</i> , 2022, 30, 1749-1757.	2.2	2
173	TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).. <i>Journal of Clinical Oncology</i> , 2013, 31, 515-515.	1.6	2
174	Digoxin as an inhibitor of global hypoxia inducible factor-1 $\pm$ (HIF1 $\pm$ ) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS1144-TPS1144.	1.6	2
175	Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative g<i>BRCA</i>-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1097-1097.	1.6	2
176	A diet low in fat and high in vegetables, fruit, and fiber following breast cancer treatment did not reduce new breast cancer events. <i>ACP Journal Club</i> , 2008, 148, 8.	0.1	2
177	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A. <i>JCO Oncology Practice</i> , 0, , .	2.9	2
178	Pharmacogenomics of Tamoxifen: Ready for Prime Time?. <i>Current Breast Cancer Reports</i> , 2010, 2, 32-41.	1.0	1
179	Reply to J.L. Blum et al and S. Lange et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 430-431.	1.6	1
180	Reply to E. Hindi-© et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2092-2093.	1.6	1

#	ARTICLE	IF	CITATIONS
181	Sensitivity for detecting PIK3CA mutations in early-stage breast cancer with droplet digital PCR.. Journal of Clinical Oncology, 2013, 31, 11019-11019.	1.6	1
182	A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testing. Quality of Life Research, 2022, 31, 2341-2355.	3.1	1
183	Pharmacogenetics of Aromatase Inhibitors: Present Understanding and Looking to the Future. Current Breast Cancer Reports, 2010, 2, 138-145.	1.0	0
184	Reply to A. Katz. Journal of Clinical Oncology, 2020, 38, 102-103.	1.6	0
185	Obesity at diagnosis and after treatment in breast cancer survivors and risk of neuropathy.. Journal of Clinical Oncology, 2018, 36, e22085-e22085.	1.6	0
186	More choices, more questions: weighing the options for treating hot flashes. The Journal of Supportive Oncology, 2006, 4, 323-5.	2.3	0
187	Abstract P5-13-09: Identifying homologous recombination deficiency in breast cancer: Genomic instability score thresholds differ in breast cancer subtypes. Cancer Research, 2022, 82, P5-13-09-P5-13-09.	0.9	0
188	Abstract P2-08-15: Clinical, pathologic, and molecular associations of tumor mutational burden in metastatic breast cancer. Cancer Research, 2022, 82, P2-08-15-P2-08-15.	0.9	0
189	YIA22-007: Adaptive Nutrition and Exercise Weight loss (A-NEW) Study for Breast Cancer Survivors With Overweight or Obesity. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, YIA22-007.	4.9	0
190	Polypharmacy and premature aromatase inhibitor (AI) discontinuation in older women with breast cancer.. Journal of Clinical Oncology, 2022, 40, 6568-6568.	1.6	0
191	Predictive value of baseline patient-rated treatment bother for early anastrozole discontinuation in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.. Journal of Clinical Oncology, 2022, 40, 12094-12094.	1.6	0
192	Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.. Journal of Clinical Oncology, 2022, 40, 525-525.	1.6	0